Sarepta Therapeutics to host conference call Conference call to discuss 48-week results from its Phase IIb study evaluating eteplirsen for the treatment of Duchenne muscular dystrophy will be held on October 3 at 8 am. Webcast Link
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.